BeiGene saw the highest growth of 1.2% in patent filings in April and 4.99% in grants in June in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 1.2% and grants by 0.32%. GlobalData’s DataBook provides a comprehensive analysis of BeiGene’s patent filings and grants. Buy the databook here.
BeiGene has been focused on protecting inventions in United States(US) with 16 publications in Q2 2024
The United States(US) Patent Office dominates the patent filings and grants with nearly 25% filings and 25% grants. The United States(US), World Intellectual Property Organization(WIPO), European Patent Office(EPO), and China(CN) patent Office are among the top ten patent offices where BeiGene is filings its patents. Among the top granted patent authorities, BeiGene has 25% of its grants in United States(US), 25% in China(CN) and 12% in European Patent Office(EPO).
Roche and Johnson & Johnson could be the strongest competitors for BeiGene
Patents related to rare diseases and climate change lead BeiGene's portfolio
BeiGene has the highest number of patents in rare diseases followed by, climate change and electronic medical record (emr) systems. For rare diseases, nearly 45% of patents were filed and 67% of patents were granted in Q2 2024.
Lymphoma related patents lead BeiGene portfolio followed by advanced malignancy, and head and neck cancer
BeiGene has highest number of patents in lymphoma followed by advanced malignancy, head and neck cancer, mantle cell lymphoma, and waldenstrom macroglobulinemia (lymphoplasmacytic lymphoma). For lymphoma, nearly 3% of patents were filed and 8% of patents were granted in Q2 2024.
For comprehensive analysis of BeiGene's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.